ERYTECH PHARMA (ERYP.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:ERYP - FR0011471135 - Common Stock
ERYP.PA Key Statistics, Chart & Performance
The current stock price of ERYP.PA is 0.801 EUR. In the past month the price decreased by -8.56%. In the past year, price decreased by -28.23%.
ERYP.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 74.11 | 49.28B | ||
| 1AE.DE | ARGENX SE | 74.35 | 49.44B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.32B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.94B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.99B | ||
| GLPG.AS | GALAPAGOS NV | 23.7 | 1.75B | ||
| 5CV.DE | CUREVAC NV | 5.11 | 1.00B | ||
| NANO.PA | NANOBIOTIX | N/A | 877.52M | ||
| PHIL.MI | PHILOGEN SPA | 20.79 | 692.99M | ||
| IVA.PA | INVENTIVA SA | N/A | 505.40M | ||
| ALCLS.PA | CELLECTIS | N/A | 411.83M | ||
| FYB.DE | FORMYCON AG | N/A | 409.06M |
Related stock screener links
About ERYP.PA
Company Profile
ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 49 full-time employees. The company went IPO on 2013-05-07. The firm offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer. The firm's technology is based on the use of human red blood cells (RBCs) to improve the pharmacokinetic (PK) and pharmacodynamic (PD) properties of therapeutic enzymes, for instance asparaginase. The enzyme can destroy asparagine and deprive cancer cells of an important nutrient for these cells, resulting in their death.
Company Info
ERYTECH PHARMA
60 avenue Rockefeller, Batiment Adenine
Lyon AUVERGNE-RHONE-ALPES FR
Employees: 49
Phone: 33478744438.0
ERYTECH PHARMA / ERYP.PA FAQ
What does ERYTECH PHARMA do?
ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 49 full-time employees. The company went IPO on 2013-05-07. The firm offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer. The firm's technology is based on the use of human red blood cells (RBCs) to improve the pharmacokinetic (PK) and pharmacodynamic (PD) properties of therapeutic enzymes, for instance asparaginase. The enzyme can destroy asparagine and deprive cancer cells of an important nutrient for these cells, resulting in their death.
Can you provide the latest stock price for ERYTECH PHARMA?
The current stock price of ERYP.PA is 0.801 EUR. The price increased by 0.25% in the last trading session.
What is the dividend status of ERYTECH PHARMA?
ERYP.PA does not pay a dividend.
What is the ChartMill rating of ERYTECH PHARMA stock?
ERYP.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of ERYTECH PHARMA (ERYP.PA) based on its PE ratio?
ERYTECH PHARMA (ERYP.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.56).
ERYP.PA Technical Analysis
ERYP.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ERYP.PA. The financial health of ERYP.PA is average, but there are quite some concerns on its profitability.
ERYP.PA Financial Highlights
Over the last trailing twelve months ERYP.PA reported a non-GAAP Earnings per Share(EPS) of -0.56. The EPS increased by 99.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.44 |
ERYP.PA Forecast & Estimates
9 analysts have analysed ERYP.PA and the average price target is 3.67 EUR. This implies a price increase of 358.43% is expected in the next year compared to the current price of 0.801.
For the next year, analysts expect an EPS growth of 22.35% and a revenue growth 16.44% for ERYP.PA